Clinical trials: Chemotherapy-induced Neutropenia
Breast Cancer, Neutropenia
Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
The overall purpose of this study is to assess the dose response, efficacy, and safety of three different dose levels of AVI 014 (granulocyte colony-stimulating factor [G-CSF]) in breast cancer patients at high (>20%) risk for…
- Trial name
- NCT00497809
- Testing
- AVI-014 versus Filgrastim
- Where
- 31 sites in United States, India
- Volunteers
- 189 people
- Sponsor
- AviGenics
Chemotherapy-induced Neutropenia, Chemotherapy-induced Nausea and Vomiting
Community-Led Action Research in Oncology: Improving Symptom Management
This study will be conducted at La Liga Contra el Cancer in San Pedro Sula, Honduras. The overall objective of this project is to improve symptom management for patients undergoing chemotherapy in Honduras.
- Conditions
- Chemotherapy-induced Neutropenia, Chemotherapy-induced Nausea and Vomiting, Anxiety, Depression
- Trial name
- CLARO (NCT03208816)
- Testing
- symptom management program for chemotherapy patients
- Where
- 2 sites in United States, Honduras
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer Female
Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.
Accelerated AC regimen-Doxorubicin 60 mg/m2,Cyclophosphamide 600 mg/m2 on day 1 \& day 14 of each cycle along with G-CSF support for up to 4 cycles, followed by Paclitaxel 175 mg/m2 in the next 4 cycles is the standard clinical…
- Trial name
- NCT03381417
- Testing
- pegcyte, Neulastim
- Where
- Vietnam
- Volunteers
- 128 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Chemotherapy-Induced Neutropenia
Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers
A Randomized, Open-Label, Single -Dose, Crossover, Phase I Clinical Trial to Evaluate the Effect of Food on the Safety, Tolerability and Pharmacokinetics of EC-18 after Oral Administration in Healthy Volunteers
- Trial name
- NCT02700360
- Testing
- high-fat diet, EC-18
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Enzychem Lifesciences Corporation
Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia
Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
Chemotherapy places patients at an increased risk of infection. A medication called granulocyte colony-stimulating factor is given as a daily injection in order to help decrease the risk of infection.
- Conditions
- Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia, Chemotherapy-Induced Febrile Neutropenia, Pediatric Cancer
- Trial name
- NCT03823950
- Testing
- Granulocyte Colony-Stimulating Factor
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Mississippi Medical Center
Prevention of Chemotherapy-induced Myelosuppression
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
This is a Phase 1b open-label, single arm, multicenter, study of ALRN-6924 as a chemoprotection agent in patients with TP53-mutated HER2- breast cancer (stages IIa to IIIb) receiving neoadjuvant or adjuvant chemotherapy with…
- Trial name
- NCT05622058
- Testing
- ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
- Where
- 14 sites in United States, Bosnia and Herzegovina and 2 more
- Volunteers
- 6 people
- Sponsor
- Aileron Therapeutics, Inc.
Neutropenia in Breast Cancer
A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer
This study primary objective and endpoints are compare the efficacy of two products containing filgrastim, evaluating if the formulation produced by Eurofarma can be considered non-inferior to the reference product.
- Trial name
- NCT01079676
- Testing
- Filgrastim (Eurofarma), Filgrastim (Granulokine, Amgen)
- Where
- 6 sites in Brazil
- Volunteers
- 220 people
- Sponsor
- Eurofarma Laboratorios S.A.
Breast Cancer
Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients
Breast cancer patients scheduled to receive myelosuppressive chemotherapy (AC regimen) will be enrolled in this study. Eligible patients receive single SC injection of pegcyte or neulastim 24 hours after administration of…
- Trial name
- NCT03376503
- Testing
- Pegfilgrastim
- Where
- Vietnam
- Volunteers
- 24 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Chemotherapy Induced Neutropenia
Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia
This study is to examine which dose of DA-3031(PEG-G-CSF) has similar efficacy and safety compared to daily G-CSF in chemotherapy-induced neutropenia.
- Trial name
- PEG-G-CSF (NCT01923545)
- Testing
- PEG-G-CSF, G-CSF
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Dong-A ST Co., Ltd.
Septic Shock, Nonchemotherapy Drug-induced Neutropenia
Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia
Septic shock remains a significant clinical problem associated with high rates of mortality among neutropenic patient despite antimicrobial therapy and supportive care.
- Conditions
- Septic Shock, Nonchemotherapy Drug-induced Neutropenia, Neutropenia After Chemotherapy in Oncohematological Patients, Neutropenia in Patients With Aplastic Anemia
- Trial name
- NCT01849237
- Testing
- Mesenchymal stromal cells, Standard therapy of septic shock
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- National Research Center for Hematology, Russia
Leukemia, Myeloid, Acute
NLA101 in Adults Receiving High Dose Chemotherapy for AML
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.
- Trial name
- LAUNCH (NCT03301597)
- Testing
- NLA101, Standard of Care (SOC) chemotherapy
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Nohla Therapeutics, Inc.
Breast Cancer, Chemotherapy-Induced Neutropenia
Correlation Between ANC and Bone Pain in Breast Cancer Patients Receiving Long-Acting G-CSF
This prospective, multicenter, non-randomized controlled study aims to evaluate bone pain associated with prophylactic use of long-acting granulocyte colony-stimulating factors (G-CSFs) in patients with breast cancer receiving…
- Conditions
- Breast Cancer, Chemotherapy-Induced Neutropenia, Febrile Neutropenia, Bone Pain
- Trial name
- Bone Pain (NCT07806084)
- Volunteers
- 132 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-Interventional Study
Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
Non-interventional, non-comparative, national, multi-site, single-arm prospective observational study to investigate home administration of Nivestim in the primary prophylaxis of chemotherapy-Induced febrile neutropenia
- Trial name
- NCT02956967
- Testing
- Overall satisfaction questionnaires of home use of Nivestim
- Where
- 28 sites in Germany
- Volunteers
- 171 people
- Sponsor
- Pfizer
Patient Preference, Febrile Neutropenia, Drug-Induced
Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim
Febrile neutropenia (NF) is a common serious complication of cancer chemotherapy. Outpatient management of chemotherapy treatments is made essential by the volume of patients treated, respect for their quality of life and the…
- Conditions
- Patient Preference, Febrile Neutropenia, Drug-Induced, Patient Satisfaction
- Trial name
- PELGRAZ (NCT05910164)
- Testing
- PELGRAZ prefilled syringe or PELGRAZ prefilled pen
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut Rafael
Neutropenia
Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF)
The purpose of this study was to analyze the clinical factors associated with the effect of Granulocyte-Colony Stimulating Factor (G-CSF).
- Trial name
- NCT03498248
- Testing
- lenograstim
- Where
- South Korea
- Volunteers
- 155 people
- Sponsor
- DERSHENG SUN
Chemotherapy-Induced Neutropenia
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
This study is a Dose block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, Phase I clinical trial to assess the safety, tolerability and pharmacokinetics of single-dose and…
- Trial name
- NCT02532712
- Testing
- EC-18
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Enzychem Lifesciences Corporation
Chemotherapy-induced Neutropenia, Cancer, Breast
Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
The purpose of this study is to evaluate the tolerance and safety of the rHSA/GCSF in breast cancer patients with different doses and multiple injections.
- Trial name
- NCT03246009
- Testing
- rHSA/GCSF
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tianjin SinoBiotech Ltd.
Early Stage Breast Cancer
A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)
In patients with early-stage breast cancer, chemotherapy has substantially improved survival rates for breast cancer patients. Improvements in outcomes, however, are compromised by the considerable toxicities associated with…
- Trial name
- React-G (NCT02428114)
- Where
- 2 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Ottawa Hospital Research Institute
Neoplasms, Chemotherapy-induced Neutropenia
Study to Evaluate the Usability of PointCheck
This a study about the usability of PointCheck a novel non-invasive technology for monitoring chemotherapy-induced neutropenia. The study will include patients with cancer visiting the outpatient hematology clinic for their…
- Trial name
- NCT04448314
- Testing
- PointCheck
- Where
- 3 sites in Spain
- Volunteers
- 94 people
- Sponsor
- Leuko Labs, Inc.
Chemotherapy-Induced Neutropenia
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy
This study is a multicenter, single-arm, prospective study. The study population includes children with cancer who require high-intensity chemotherapy.
- Trial name
- Telpegfilgrast (NCT06857292)
- Testing
- Telpegfilgrastim
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Sun Yat-sen University